Literature DB >> 10750377

Update on psoriasis therapy: a perspective from the USA.

J Koo1, W Liao.   

Abstract

Because physicians from different nations frequently acquire the use of a new medication at different times, the international exchange of experiences with the new medication is valuable in maximizing its efficacy worldwide. In recent years, many new therapeutic agents have been approved for treating psoriasis in the United States. These include the topical agent calcipotriol and the systemic agents acitretin and cyclosporine. In addition to new agents, a new therapeutic paradigm, sequential therapy, has been introduced recently. It is the hope of the authors that by sharing this paradigm and experiences with these agents in the United States, dermatologists in Japan may gain further insight into optimizing the use of these agents in the treatment of psoriasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10750377     DOI: 10.2302/kjm.49.20

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  3 in total

Review 1.  Clinical efficacy and safety of using calcipotriol-betamethasone compounding agent for psoriasis treatment: a systematic review and meta-analysis.

Authors:  Junrong Ren; Qi Zhu; Siyao Wang; Xiaolong Li; Zhen Sun; Nan Li; Jian Feng; Haining Ding; Sitong Dong; Hongmei Wang
Journal:  Arch Dermatol Res       Date:  2021-08-20       Impact factor: 3.033

2.  The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice.

Authors:  Chong Won Choi; Bo Ri Kim; Jungyoon Ohn; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2017-02-03       Impact factor: 1.444

3.  Cyclosporine A stimulated hair growth from mouse vibrissae follicles in an organ culture model.

Authors:  Wenrong Xu; Weixin Fan; Kun Yao
Journal:  J Biomed Res       Date:  2012-03-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.